David M. Weiner, MD
Chief Medical Officer

Dave Weiner most recently served as the chief executive officer at Amathus Therapeutics. He has over 25 years of experience in the discovery and clinical development of novel therapeutics for neurological and rare diseases. He started his career at Acadia Pharmaceuticals where, over a ten-year period, he held a series of discovery research and clinical development roles working on multiples CNS therapeutics—most notably Pimavanserin, which is approved for the treatment of Parkinson’s disease (PD) psychosis. He has extensive development experience in PD, advancing both small molecole (Safinamide) and gene therapy (CERE-120) approaches.

Dr. Weiner served as chief medical officer and interim CEO for Proteostasis Therapeutics, and as CMO at aTyr Pharma and Lumos Pharma. He received his M.D. from the School of Medicine and Biomedical Sciences at University of Buffalo-SUNY, and was a Howard Hughes Medical Institute Research Scholar at NIH Bethesda. He trained in clinical neurology at New York Hospital, Memorial Sloan Kettering, and Cornell Medical Center, and did a post-doctoral fellowship in neuropharmacology at the University of Vermont.

Dave has authored over 30 scientific publications and multiple patents, and serves on multiple clinical and scientific advisory boards, including the Michael J. Fox Foundation for Parkinson’s Research.